Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.59 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.59 |
| ▸ | PDE2A | O00408 | 1/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | NT5E | P21589 | 6/20 | 0.54 |
| ▸ | PNP | P00491 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1591903 | 1.00 | ADORA2A (0.60) | ADORA2AADORA3PDE4DPDE3APDE2A | |
| SCHEMBL12702741 | 1.00 | ADORA2A (0.60) | ADORA2AADORA3PDE4DPDE3APDE2A | |
| SCHEMBL12702689 | 1.00 | ADORA2A (0.60) | ADORA2AADORA3PDE4DPDE3APDE2A | |
| SCHEMBL12702703 | 1.00 | ADORA2A (0.60) | ADORA2AADORA3PDE4DPDE3APDE2A | |
| SCHEMBL12702738 | 1.00 | ADORA2A (0.60) | ADORA2AADORA3PDE4DPDE3APDE2A | |
| SCHEMBL19987331 | 0.90 | ADORA3 (0.59) | ADORA2AADORA3PDE4DPDE3APDE2A | |
| SCHEMBL19974382 | 0.90 | ADORA3 (0.59) | ADORA2AADORA3PDE4DPDE3APDE2A | |
| SCHEMBL19948532 | 0.88 | ADORA2A (0.67) | ADORA2AADORA3PDE4DPDE3APDE2A | |
| SCHEMBL30262589 | 0.88 | ADORA2A (0.67) | ADORA2AADORA3PDE4DPDE3APDE2A | |
| SCHEMBL1591764 | 0.85 | NT5E (0.48) | ADORA2AADORA3ADORA1NT5ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2265626-B1 | NUCLEOTIDE ANALOGUES WITH QUATERNARY CARBON STEREOGENIC CENTERS AND METHODS OF USE | LCB PHARMA INC (CA) | 2019-05-15 | — | — | EP | disclosed |
| US-8846636-B2 | Nucleoside analogues with quaternary carbon stereogenic centers and methods of use | LCB PHARMA INC. (CA) | 2014-09-30 | — | — | US | disclosed |
| US-20110092451-A1 | NUCLEOTIDE ANALOGUES WITH QUATERNARY CARBON STEREOGENIC CENTERS AND METHODS OF USE | INSTITUT DE RECHERCHES CLINIQUES DE MONTREAL (CA) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092451-A1 | NUCLEOTIDE ANALOGUES WITH QUATERNARY CARBON STEREOGENIC CENTERS AND METHODS OF USE | NUDT1, NT5C3B, NTPCR | ADORA2A 505/4885ADORA3 199/4885PDE4D 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.